Dr. Agarwal's Health Care Limited Q4 FY25 earnings call summary

Earnings call of 29 May 2025, summarised by AI from the filing.

Premiumization, higher surgical volumes and new facilities drove revenue growth.

Key takeaways

1. Growth driver Premiumization, higher surgical volumes and new facilities drove revenue growth.
2. Risk EBITDA margin impacted by greenfield investments, marketing and one-time expenses.

Original filing on BSE

Dr. Agarwal's Health Care Limited Q1 FY27 results

As filed: Revenue ₹614 cr (+26% year on year), EBITDA ₹170 cr (+32% year on year), PAT ₹55.0 cr (+45% year on year), EBITDA margin 27.8% (+126 bps).

The Q1 FY27 score, against the company's own trend, is for premium members.

Earlier results and the share price after them

• Q4 FY26: Revenue ₹564 cr (+23% year on year), EBITDA ₹161 cr (+22% year on year), PAT ₹50.0 cr (+16% year on year), EBITDA margin 28.6% (−7 bps). Score 59 of 100, In line with trend. EBITDA margin was flat year on year. Consolidated profit +16% but standalone -61%. Not enough history for a trend yet: scored on growth alone. Share price after the results: −3.0% in 29 days (Nifty 500: +2.4%).
• Q3 FY26: Revenue ₹530 cr (+23% year on year), EBITDA ₹144 cr (+26% year on year), PAT ₹43.6 cr (+56% year on year), EBITDA margin 27.2% (+75 bps). Score 77 of 100, Above trend. EBITDA margin rose 75 bps year on year. Not enough history for a trend yet: scored on growth alone. Share price after the results: −0.2% in 30 days (Nifty 500: −3.2%).
• Q2 FY26: Revenue ₹499 cr, EBITDA ₹137 cr, PAT ₹36.0 cr, EBITDA margin 27.5%. Not scored. No consolidated results for the same quarter last year to compare yet (consolidated revenue ₹499 cr). Scored once a year-earlier consolidated quarter exists. Share price after the results: +2.9% in 29 days (Nifty 500: +0.4%).
• Q1 FY26: Revenue ₹487 cr, EBITDA ₹129 cr, PAT ₹38.0 cr, EBITDA margin 26.5%. Not scored. No consolidated results for the same quarter last year to compare yet (consolidated revenue ₹487 cr). Scored once a year-earlier consolidated quarter exists. Share price after the results: −5.3% in 30 days (Nifty 500: +2.4%).
• Q4 FY25: Revenue ₹460 cr, EBITDA ₹132 cr, PAT ₹43.0 cr, EBITDA margin 28.7%. Not scored. No consolidated results for the same quarter last year to compare yet (consolidated revenue ₹460 cr). Scored once a year-earlier consolidated quarter exists. Share price after the results: +12.7% in 30 days (Nifty 500: +3.7%).
• Q3 FY25: Revenue ₹431 cr, EBITDA ₹114 cr, PAT ₹28.0 cr, EBITDA margin 26.5%. Not scored. No consolidated results for the same quarter last year to compare yet (consolidated revenue ₹431 cr). Scored once a year-earlier consolidated quarter exists.

Past price moves after results do not indicate future moves. Not a recommendation.

Dr. Agarwal's Health Care Limited earnings call, investor presentation and press release summaries

• Q1 FY27: Earnings call (4 Aug 2026), Results deck (4 Aug 2026)
• Q4 FY26: Earnings call (21 May 2026), Results deck (21 May 2026)
• Q3 FY26: Earnings call (4 Feb 2026), Results deck (3 Feb 2026)
• Q2 FY26: Earnings call (31 Oct 2025), Results deck (31 Oct 2025)
• Q1 FY26: Earnings call (12 Aug 2025), Results deck (12 Aug 2025)
• Q4 FY25: Earnings call (29 May 2025), Results deck (29 May 2025)
• Other events: Special call (28 Aug 2025), Strategy deck (27 Aug 2025)